Julian Gabor

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Placental Malaria Increases Malaria Risk in the First 30 Months of Life

Norbert Georg Schwarz, Ayôla Akim Adégnika, Lutz P. Breitling et al. · Clinical Infectious Diseases · 2008 · 132 citations · Full text

Public Health, Infectious Diseases, Maternal Health +17

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 132 citations · Full text

Veterinary Medicine, Immunology, Molecular Pharmaceutics +17

Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial

Geert Leroux‐Roels, Arnaud Marchant, Jack Lévy et al. · Clinical Immunology · 2016 · 115 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

Dorothee Kieninger, Eric Sheldon, Wen‐Yuan Lin et al. · BMC Infectious Diseases · 2013 · 104 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +11